Portal de Periódicos da CAPES

Biphasic decay of cell-associated HIV-1 DNA in HIV-1-infected children on antiretroviral therapy

2002; Lippincott Williams & Wilkins; Volume: 16; Issue: 14 Linguagem: Inglês

10.1097/00002030-200209270-00015

1473-5571

Anita De Rossi, A. Sarah Walker, Davide De Forni, Diana M. Gibb,

HIV/AIDS drug development and treatment

Cell-associated HIV-1 DNA was quantified in 33 HIV-1-infected children followed for 96 weeks after the initiation of antiretroviral therapy. HIV-1 DNA decay was biphasic, being 10-fold more rapid during the first 4 weeks, and was inversely associated with the baseline plasma HIV-1-RNA level, but unrelated to HIV-1-RNA suppression. HIV-1 DNA decay per absolute CD4 cell number was lower than per 106 CD4 cells, suggesting an ongoing infection of newly produced CD4 cells, despite HIV-1 suppression in plasma. It is well established that despite the strong inhibition of viral replication in patients on antiretroviral therapy (ART), HIV-1 may persist in peripheral blood cells and lymphoid tissues. We assessed the relationship between changes in cell-associated HIV-1 DNA and plasma HIV-1 RNA in a subset of 33 ART-naive children initiating therapy in the PENTA 5 trial [1], with a median age of 7.1 years (range 0.3–15.5), CD4 cell percentage 17% (interquartile range 9–24%), and mean HIV-1-RNA level 5.01 log10 copies/ml (SD 0.76) at baseline. Children were randomly assigned to receive zidovudine/lamivudine (n = 8), zidovudine/abacavir (n = 13) and lamivudine/abacavir (n = 12). Sixteen children with more advanced disease also received nelfinavir; and 17 with asymptomatic disease received nelfinavir (n = 10) or placebo (n = 7) in a second randomization. Cell-associated HIV-1 DNA was measured in peripheral blood mononuclear cells (PBMC) at baseline, and at 4, 12, 24, 48 and 96 weeks. HIV-1-DNA quantification was performed using real-time polymerase chain reaction [2]. HIV-1 DNA copy numbers were normalized to the number of β-actin genes, and expressed relative to 106 PBMC (2 × 106 β-actin copies), and to 106 CD4 cells, by attributing the HIV-1-DNA load to the CD4 cell fraction, given that these cells are the main target of HIV-1 infection. Children in PENTA 5 experienced substantial increases in CD4 cell counts during the trial [1], so HIV-1-DNA copy numbers per cell were also transformed to copy numbers per millilitre of blood by taking into account the total number of CD4 cells per millilitre. HIV-1-RNA levels were determined using the Roche Amplicor assay (version 1.5; Roche Diagnostic Systems, Inc., Branchburg, NJ, USA). Normal interval regression [3] was used to estimate the mean absolute levels of and change in log10 HIV-1 DNA and HIV-1 RNA, replacing undetectable values with the interval in which the true value could lie (the interval up to the cut-off), and adjusting for multiple measurements on each child [4]. Overall, there was a significant decrease in log10 HIV-1-DNA copies in PBMC and CD4 cells after baseline (both P < 0.0001, Fig. 1(a) and (b)). Declines in HIV-1 DNA per 106 PBMC and 106 CD4 cells were 0.06 [95% confidence interval (CI) 0.02–0.10; P = 0.003] and 0.09 (0.05–0.13; P < 0.001) log10 copies per week, respectively, to week 4; followed by slower declines of 0.005 (0.002–0.007; P = 0.001) and 0.008 (0.004–0.012; P < 0.001) log10 copies per week in PBMC and CD4 cells, respectively, from 4 to 96 weeks. Expressing HIV-1-DNA copies per millilitre of blood to incorporate changes in CD4 cells, decreases of 0.06 log10 copies per week to week 4 (0.02–0.10; P = 0.005) and 0.005 log10 copies per week from 4 to 96 weeks (0.002–0.008; P < 0.001) were observed (Fig. 1(c) and (d)), which were lower than that estimated per 106 CD4 cells.Fig. 1.: HIV-1-DNA copies per 106 cells and per millilitre, and HIV-1-RNA copies per millilitre after initiation of antiretroviral therapy. (a) Change in log10 HIV-1-DNA copies per 106 cells. ––•–– Peripheral blood mononuclear cells (PBMC), ––○–– CD4 cells; (b) absolute HIV-1-DNA copies per 106 cells ––•–– PBMC, ––○–– CD4 cells; (c) change in log10 HIV-1-DNA and plasma HIV-1-RNA copies per millilitre. - - - • - - - HIV-1 DNA, - - - ○ - - - plasma HIV-1 RNA; (d) absolute log10 HIV-1-DNA and plasma HIV-1-RNA copies per millilitre. - - - • - - - HIV-1 DNA, - - - ○ - - - plasma HIV-1 RNA. aCalculated as mean (95% confidence interval) absolute log10 copies and back-transformed to absolute copies.Higher baseline plasma HIV-1-RNA levels were associated with a faster decline in HIV-1 DNA in the first 4 weeks (0.06 steeper slope for 1 log10 higher baseline HIV-1-RNA level; P = 0.04), but not after 4 weeks (P = 0.99). At week 4, no child had a plasma HIV-1-RNA level of less than 50 copies/ml, and only eight children (33%) had HIV-1-RNA levels of less than 400 copies/ml. Thirty children (91%) achieved HIV-1-RNA levels of less than 400 copies/ml and 19 (58%) less than 50 copies/ml at some time during follow-up. There was no evidence of a greater decline in HIV-1-DNA levels at timepoints when children had HIV-1-RNA levels of less than 50 copies/ml; if anything, changes in the HIV-1-DNA level were 0.07 log10 copies per millilitre smaller at these assessments (P = 0.63; 95% CI 0.37 smaller to 0.22 greater change from baseline at timepoints with HIV-1-RNA levels < 50 copies/ml). A higher baseline CD4 cell percentage was not associated with a decline in HIV-1-DNA level per 106 CD4 cells (P = 0.58), but was marginally associated with a faster decline in the HIV-1-DNA level per millilitre in the first 4 weeks (0.01 steeper slope for 5% higher baseline CD4%; P = 0.11). This is consistent with smaller increases in CD4 cell counts during ART in children with higher baseline CD4 cell percentages [2]. The overall change in plasma HIV-1 RNA per millilitre was 0.60 log10 copies per week to 4 weeks (95% CI 0.51–0.68; P < 0.0001), and 0.007 log10 copies per week from 4 to 96 weeks (0.001–0.010; P = 0.03). Although higher baseline HIV-1-DNA levels were associated with less steep initial and subsequent slopes in plasma HIV-1-RNA levels, neither interaction was statistically significant (both P = 0.16). However, children with higher baseline HIV-1-DNA levels had a lower chance of subsequently achieving plasma HIV-1-RNA levels of less than 50 copies/ml (odds ratio 0.54 for 1 log10 higher baseline HIV-1-DNA level; 95% CI 0.29–1.00; P = 0.05), whereas there was no significant effect of the baseline plasma HIV-1-RNA level (P = 0.25). In conclusion, our data show that after the initiation of ART the decay of cell-associated HIV-1 DNA is biphasic, with a rapid decrease during the first 4 weeks followed by a slower decline, similar to that observed for HIV-1 RNA, and in contrast with previous observations in adults [5]. We found that the higher the baseline HIV-1-RNA level the faster the initial decline in the HIV-1-DNA level, but that there was no association between the suppression of plasma HIV-1-RNA and HIV-1-DNA levels during ART. The decrease in the HIV-1-DNA level per millilitre of blood was lower than that estimated per 106 CD4 cells, mostly because of ongoing increases in CD4 cells, which are the main target of HIV-1 infection, and did not differ significantly in children with or without HIV-1-RNA suppression. The persistence of HIV-1 DNA may result both from latently infected cells with a long half-life and newly infected cells [6,7]. Together with the evidence that the peripheral increase in CD4 cells mainly consists of naive cells [1,8], these data strongly suggest that viral replication and the infection of newly produced CD4 cells occur in children on ART, regardless of their apparent HIV-1 suppression in plasma. PENTA Committees and Participants Virology Committee C. Boucher, A. de Rossi, C. Loveday, M. Muñoz Fernandez, D. Pillay, C. Rouzioux, S. Kaye Centres Participating in HIV-1-DNA substudy: Virologists/immunologistsc Italy: Ospedale Meyer, Florence: L. Galli, M. de Martino; Ospedale Civile, Modena: M. Cellini, C. Baraldi, M. Portolanic, M. Meaccic, P. Pietrosemolic; Università di Padova: C. Giaquinto, V. Giacomet, R. D'Elia, A. de Rossic, M. Zanchettac, D. de Fornic; IRCCS Policlinico San Matteo, Pavia: D. Caselli, A. Maccabruni, E. Cattaneoc, V. Landinic; Ospedale Bambino Gesò, Rome: G. Castelli-Gattinara, S. Bernardi, A. Krzysztofiak, C. Tancredi, P. Rossic, L. Pansanic; Ospedale S. Bortolo, Vicenza: R. Nicolin, A. Timillero. UK: Bristol Royal Hospital for Sick Children, Bristol: A. Foot, H. Kershaw; PHL Regional Virus Laboratory, Bristol: O. Caulc; Ninewells Hospital and Medical School, Dundee: W. Tarnow-Mordi, J. Petrie, P. McIntyrec, K. Appleyardc; Great Ormond St Hospital for Children NHS Trust, London: D. Gibb, V. Novelli, N. Klein, L. McGee, S. Ewen, M. Johnsonc; Newham General Hospital, London: D.M. Gibb, E. Cooper, T. Fisher, R. Barrie; St Bartholemew's Hospital, London: J. Normanc; University College London Medical School, London: S. Kayec. Acknowledgements The authors would like to thank all the children, families and staff from all the centres participating in the PENTA 5 trial. Sponsorship: PENTA is a Concerted Action of the European Commission, supported by BIOMED 2 contract BMH4-CT96-0836 and by contract QLK2-2000-00150. UK and Italian centres received support for the PENTA 5 trial from the Medical Research Council, UK, and Istituto Superiore di Sanita, Italy, respectively. Glaxo-Wellcome and Agouron provided drugs for the trial and contributed funding to undertake the PENTA 5 trial, but were not involved in this substudy.